IPO momentum Mobia Medical recently filed for an IPO and raised approximately $150M, signaling strong investor confidence and a platform for accelerated market expansion and sales efforts into hospitals and stroke rehabilitation centers.

Strong revenue growth Revenue has shown notable growth, with recent reports indicating quarterly revenue around $13.5M and annualized projections in the $25M–$50M range, suggesting expanding adoption of the Vivistim system among stroke survivors and referral networks.

Strategic leadership Addition of independent director Myriam Curet strengthens governance and strategic guidance, creating opportunities to leverage her network for partnerships with clinical authorities, health systems, and payer conversations essential for rollout.

Product-market fit Vivistim Paired VNS Therapy is FDA-approved for specific stroke impairments, presenting a differentiated value proposition for neurorehabilitation programs and payers seeking outcomes in upper-extremity recovery and neuroplasticity-driven therapy.

Expansion readiness Current capital raise and IPO plans, combined with rapid revenue growth and a commercial-stage product, position Mobia for scaling sales teams, strategic vision partnerships, and accelerated placement in hospital systems and rehab networks.